TRPM5 Ion Channel Modulation for Skin Pigmentation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skin pigmentation conditions, such as hyperpigmentation and hypopigmentation, often come with undesirable side effects and do not specifically target melanocytes or the melanogenesis process.
Innovation Solution
The use of an active agent that modulates the activity of the transient receptor potential ion channel TRPM5, either by activating, enhancing, inactivating, or blocking the channel, or by dampening the cellular response induced by TRPM5, to regulate skin pigmentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional skin lightening agents (vitamins, phenolic compounds) are used to treat hyperpigmentation, then some pigmentation suppression effect is achieved, but significant adverse side effects occur and safety concerns arise
Solution Approach 1:
The patent introduces TRPM5 ion channel as an intermediary target between UV radiation and melanin synthesis. By modulating this ion channel's activity, the patent achieves pigmentation regulation without directly using harmful agents like hydroquinone or broad-spectrum antioxidants, thereby eliminating adverse side effects while maintaining therapeutic efficacy
Solution Approach 2:
The patent changes the physiological parameter of ion channel activity (TRPM5) to regulate skin pigmentation. By activating or inhibiting this specific ion channel, the patent achieves precise control over melanin production, replacing the non-specific action of conventional agents with a targeted physiological modulation that improves safety
2Reliability
If conventional skin lightening agents are used, then pigmentation suppression is achieved, but the agents do not specifically target melanocytes or the melanogenesis process
Solution Approach 1:
The patent applies local quality by targeting a specific ion channel (TRPM5) expressed specifically in melanocytes and epidermal cells. This localized molecular target ensures that the active agent acts precisely where needed—in the melanogenesis pathway—rather than requiring broad-spectrum mechanisms that affect the entire skin ecosystem
Solution Approach 2:
The patent replaces the non-specific mechanical action of conventional agents (antioxidant scavenging, general cell protection) with a specific biochemical mechanism involving ion channel modulation. This substitution enables direct interference with the melanogenesis process through TRPM5 activity, achieving both specificity and mechanistic clarity
3Reliability
If phenolic compounds like hydroquinone are used to inhibit tyrosinase, then effective hyperpigmentation treatment is achieved, but chronic adverse effects and carcinogenesis risk occur
Solution Approach 1:
The patent converts the harmful effect of UV-induced ion channel activation into a beneficial therapeutic mechanism. By targeting TRPM5, which is naturally activated by UV radiation to trigger melanogenesis, the patent can now modulate this same pathway to treat hyperpigmentation, turning a harmful UV response into a controllable therapeutic mechanism that eliminates carcinogenesis risk
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The active agent effectively promotes or inhibits skin pigmentation by upregulating or downregulating melanin production, as demonstrated by increased epidermal melanin content, enhanced tyrosinase activity, and increased expression of premelanosome protein gp100, without causing significant side effects.
Implementation Method 1
the active agent modulates the activity of an ion channel, including but not limited to activation, enhancement, inactivation or blocking an ion channel
Implementation Method 2
UV radiation-induced DNA damage stimulates melanogenesis through the up-regulation and activation of tyrosinase, the enzyme that catalyzes the rate-limiting step of melanin synthesis
Data Source
AI summary
Active agents are used for actively controlling and/or treating skin pigmentation in subjects without undesired side effects by activating, enhancing, inactivating, blocking or dampening the cellular response of the transient receptor potential ion channel TRPM5 or interfering with the expression of the ion channel.